for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Genmab Says CHMP Issues Positive Opinion Recommending Subcutaneous Formulation Of Daratumumab For The Treatment Of Patients With Multiple Myeloma

April 30 (Reuters) - Genmab A/S:

* REG-CHMP ISSUES POSITIVE OPINION RECOMMENDING SUBCUTANEOUS FORMULATION OF DARATUMUMAB FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

* GENMAB A/S - OPINION BASED ON DATA FROM PHASE III COLUMBA AND PHASE II PLEIADES STUDIES COPENHAGEN, DENMARK Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up